Exploratory analyses of OS and PFS by PDGFR-α and PDGFR-β tumor status found no association between PDGFR-α or PDGFR-β expression and olaratumab response in the O-naïve or O-pretreated cohorts (Table S3). The gene discussed is PDGFRA; the disease is neoplasm.